Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

This study is testing a new form of enzalutamide — a drug used to treat prostate cancer — delivered as an implant directly into the prostate rather than as a daily pill. The goal is to see whether this localized approach can shrink the cancer before surgical removal of the prostate. **You may be eligible if...** - You are at least 21 years old - You have been diagnosed with prostate cancer confirmed by biopsy - Your cancer is moderate-to-high risk (Gleason score 3+3 with high-risk features, or 3+4 or higher) - You are already planned to have your prostate surgically removed (radical prostatectomy) - Your prostate has at least one measurable lesion on MRI - Your blood counts, kidney, and liver function meet minimum levels **You may NOT be eligible if...** - You have had prior radiation or surgery for prostate cancer - You are currently on or recently completed hormone therapy for prostate cancer (within 3 months) - You have significant heart, kidney, or liver problems - You are unwilling to use effective contraception during and for 3 months after the study Talk to your doctor to see if this trial is right for you.